Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Eberhardt, W. E. E., Rebmann, V., Rizvi, N., Antonia, S. J., Planchard, D., Cappuzzo, F., Mazieres, J., Zalcman, G., Lena, H., Wolf, J., Horn, L., Stinchcombe, T., Dy, G., Blackwood-Chirchir, A., Jin, C., Geese, W. J. and Ramalingam, S. S. (2017). First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO): checkMate 063. Oncol. Res. Treat., 40. S. 218 - 220. BASEL: KARGER. ISSN 2296-5262

Lena, H., Rizvi, N. A., Wolf, J., Cappuzzo, F., Zalcman, G., Baas, P., Mazieres, J., Farsaci, B., Blackwood-Chirchir, M. A. and Ramalingam, S. (2016). Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses. J. Thorac. Oncol., 11 (4). S. S115 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Ramalingam, S. S., Mazieres, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Baudelet, C., Lestini, B. J. and Rizvi, N. A. (2014). Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys., 90 (5). S. 1266 - 1268. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

This list was generated on Thu Mar 28 21:50:21 2024 CET.